Previously based on immunochemistry, genomic discoveries led to a new subgroup classification, with the identification of four molecular subtypes (luminal A, luminal B, basal-like and HER2-enriched) in BC, associated with different outcomes and treatment response [9,10,11,12]. This evidence concerns the gene ERBB2 and breast cancer.